loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Rivoceranib

    Client Email Product
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-09-09

    Virtual Booth

    Contact Supplier

    Menu

    Rivoceranib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Elevar Therapeutics Gets EU Orphan Drug Designation For HCC Therapy
    Elevar Therapeutics Gets EU Orphan Drug Designation For HCC Therapy

    01 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/01/2922906/0/en/Elevar-Therapeutics-Granted-Orphan-Medicinal-Product-Designation-by-the-European-Medicines-Agency-for-First-Line-Systemic-Therapy-for-Unresectable-Hepatocellular-Carcinoma.html

    GLOBENEWSWIRE
    01 Aug 2024
    Share Share
    FDA rejects Elevar, Hengrui's PD-1 combo
    FDA rejects Elevar, Hengrui's PD-1 combo

    18 May 2024

    // FIERCE PGARMA

    https://www.fiercepharma.com/pharma/fda-pd-1-combo-elevar-hengrui-camrelizumab-liver-cancer

    FIERCE PGARMA
    18 May 2024
    Share Share
    HLB fails to win US FDA's approval for Rivoceranib liver cancer drug
    HLB fails to win US FDA's approval for Rivoceranib liver cancer drug

    17 May 2024

    // KOREATIMES

    https://www.koreatimes.co.kr/www/nation/2024/05/129_374825.html

    KOREATIMES
    17 May 2024
    Share Share
    Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab
    Jiangsu Hengrui and Elevar Therapeutics Announce Agreement for Camrelizumab

    17 Oct 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2023/10/17/2761595/0/en/Jiangsu-Hengrui-Pharma-and-Elevar-Therapeutics-Announce-Global-Commercialization-Licensing-Agreement-for-PD-1-Inhibitor-Camrelizumab-in-Combination-with-Rivoceranib-for-uHCC.html

    GLOBENEWSWIRE
    17 Oct 2023
    Share Share
    Elevar to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib
    Elevar to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib

    03 Aug 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/08/03/2718088/0/en/Elevar-Therapeutics-to-Host-August-10-Virtual-KOL-Event-on-Phase-3-Study-of-Rivoceranib-in-Combination-with-Camrelizumab-in-Unresectable-Hepatocellular-Carcinoma-uHCC.html

    GLOBENEWSWIRE
    03 Aug 2023
    Share Share
    Elevar Announces Acceptance for Filing of NDA for Rivoceranib with Camrelizumab
    Elevar Announces Acceptance for Filing of NDA for Rivoceranib with Camrelizumab

    17 Jul 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/07/17/2705640/0/en/Elevar-Therapeutics-Announces-FDA-Acceptance-for-Filing-of-New-Drug-Application-for-Rivoceranib-in-Combination-with-Camrelizumab-as-a-First-line-Treatment-for-Unresectable-Hepatoce.html

    GLOBENEWSWIRE
    17 Jul 2023
    Share Share